Nivolumab biosimilar (Polpharma Biologics)

纳武利尤单抗生物类似药（Polpharma Biologics）

Report date: 2025/02/18 10:49:57

Base Information

Drug NameNivolumab biosimilar (Polpharma Biologics)
Drug Alias NamePB-015
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 inhibitors
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPolpharma Biologics Sa
China Registration ClassN/A

Develop Information

Active CompaniesPolpharma Biologics Sa
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A